Advertisements

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant.....»»

Category: press-releasesSource: businesswireindiaJul 12th, 2018

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma.....»»

Category: press-releasesSource: businesswireindiaOct 3rd, 2018

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib in Patients with ALK+ Advanced NSCLC Who are ALK Inhibitor Naïve.....»»

Category: press-releasesSource: businesswireindiaJul 25th, 2018

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting.....»»

Category: press-releasesSource: businesswireindiaJun 24th, 2017

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

Merck, Pfizer combo treatment meets main goals of kidney cancer trial.....»»

Category: topSource: moneycontrolOct 18th, 2018

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer.....»»

Category: press-releasesSource: businesswireindiaOct 20th, 2018

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis

New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis.....»»

Category: press-releasesSource: businesswireindiaJul 19th, 2018

Lupin to file application for biosimilar etanercept in EU, Japan in next quarter

Lupin to file application for biosimilar etanercept in EU, Japan in next quarter.....»»

Category: featuresSource: livemintFeb 7th, 2018

Lynparza (olaparib) Maintenance Treatment Offers Sustained Quality of Life alongside Improved Progression-Free Survival in Women with BRCA-Mutated Ovarian Cancer

Lynparza (olaparib) Maintenance Treatment Offers Sustained Quality of Life alongside Improved Progression-Free Survival in Women with BRCA-Mutated Ovarian Cancer.....»»

Category: press-releasesSource: businesswireindiaJun 3rd, 2017

Glenmark to launch phase 1 trial in solid tumors for anti-myeloma drug

Glenmark to launch phase 1 trial in solid tumors for anti-myeloma drug.....»»

Category: topSource: moneycontrolNov 8th, 2018

AbbVie rheumatoid arthritis drug succeeds in late stage trial

AbbVie rheumatoid arthritis drug succeeds in late stage trial.....»»

Category: global-financeSource: reutersOct 23rd, 2018

New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018.....»»

Category: press-releasesSource: businesswireindiaOct 10th, 2018

Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint

Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint.....»»

Category: press-releasesSource: businesswireindiaOct 9th, 2018

Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint

Boehringer Ingelheim and Lilly announce Trajenta®’s CARMELINA® cardiovascular outcome trial met its primary endpoint.....»»

Category: press-releasesSource: businesswireindiaJul 20th, 2018

Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma

Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma.....»»

Category: press-releasesSource: businesswireindiaJun 2nd, 2018

Buy Vedanta, target Rs 425: Sumit Bilgaiyan

Buy Vedanta, target Rs 425: Sumit Bilgaiyan.....»»

Category: topSource: moneycontrolApr 12th, 2018

Merck KGaA, Pfizer"s immunotherapy fails in lung cancer trial

Merck KGaA, Pfizer"s immunotherapy fails in lung cancer trial.....»»

Category: global-financeSource: reutersFeb 15th, 2018

Dr. Reddy’s unveils cancer drug in U.S.

Dr. Reddy’s unveils cancer drug in U.S......»»

Category: topSource: the-hinduDec 26th, 2017

Infra sector returning to normalisation post temporary blips: CMIE

Infra sector returning to normalisation post temporary blips: CMIE.....»»

Category: topSource: moneycontrolDec 14th, 2017

Glenmark completes phase 3 study for nasal spray

Glenmark completes phase 3 study for nasal spray.....»»

Category: topSource: moneycontrolDec 14th, 2017

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris.....»»

Category: topSource: moneycontrolDec 13th, 2017